MedTrace Logo

A Study to Investigate the PK and Safety of CKD-393

NCT04768673 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2021-08-02

No results posted yet for this study

Summary

A clinical trial to investigate the pharmacokinetics and safety after oral administration of CKD-393

Conditions

  • Type II Diabetes

Interventions

DRUG

CKD-393 formulation I

single, oral administration of 2 tablets under fed condition

DRUG

CKD-393 formulation II

single, oral administration of 2 tablets under fed condition

DRUG

D501, D759, H053

single, oral administration of 1 D501, 1 D759 and 2 H053 under fed condition

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Min Soo Park, MD, Ph.D · Severance Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-26
Primary Completion
2021-04-22
Completion
2021-04-27

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04768673 on ClinicalTrials.gov